한국산학기술학회논문지 (Journal of the Korea Academia-Industrial cooperation Society)

  • 제20권2호
  • /
  • Pages.681-693
  • /
  • 2019
  • /
  • 1975-4701(pISSN)
  • /
  • 2288-4688(eISSN)
한국산학기술학회 (The Korea Academia-Industrial cooperation Society)
권호 표지
DOI QR코드

DOI QR Code

다회용 점안제의 개봉 후 안정성 평가 -올로파타딘, 플루오로메톨론, 도르졸라미드, 티몰롤 약물 중심-

The in-use stability study of multi-use ophthalmic solutions -Focused on Olopatadine, Fluorometholone, Dorzolamide, Timolol-

  • 신서영 (성균관대학교 약학대학) ;
  • 장경원 (대원대학교 제약품질관리과) ;
  • 선상욱 (동신대학교 제약공학과) ;
  • 하동문 (성균관대학교 약학대학)
  • Shin, Seo-young (School of Pharmacy, Sungkyunkwan University) ;
  • Jang, Kyoung won (Department of Pharmaceutical Quality, Daewon University College) ;
  • Sun, Sangouk (Department of Pharmaceutical Engineering, Dongshin University) ;
  • Ha, Dongmun (School of Pharmacy, Sungkyunkwan University)
  • 투고 : 2018.10.15
  • 심사 : 2019.02.01
  • 발행 : 2019.02.28
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

다회용 점안제는 개봉 후 여러 번 사용되기 때문에 사용 중 품질저하 가능성이 높다. 다회용 점안제의 개봉 후 안정성 평가 관련 국내외 규정의 비교분석을 통해 제제별 안정성을 평가하여 개봉 후 안전한 사용기간을 제안하고자 한다. 국내에서 다빈도로 사용중인 다회용 점안제 4종(올로파타딘염산염(Olo), 플루오로메톨론(Flu), 도르졸라미드염산염(Dor), 티몰롤말레산염(Timol))을 대상으로 개봉 후 실제 사용방법에 따른 보관조건을 통해 안정성을 평가하였다. 연구결과 Olo는 개봉 2개월 이후 주성분 및 보존제 함량이 감소하였고, Flu는 개봉 후 28일 차부터 함량이 감소되었다. Dor와 Timol 복합점안제의 경우 Dor은 함량 및 유연물질이 개봉 후 14일부터, Timol의 함량은 개봉 후 28일부터 안정성 저하를 보였다. Olo, Flu은 개봉 후 28일 이내로, Dor, Timol은 개봉 후 14일 이내에만 사용되어야 한다. 무균제제인 다회용 점안제는 개봉 후 안정성 평가를 통해 사용기간 설정에 대한 규제제도 개선이 필요함을 제언하고자 한다.

Multi-use ophthalmic solutions are used many times after opening; therefore, there is a high possibility of decreased quality during use. This study was conducted to determine the recommended use period of multi-use ophthalmic solutions based on evaluation of the stability by comparing stability evaluation regulations of the USA, EU and Korea We selected four types of multi-use ophthalmic solutions (Olopatadine (Olo), Fluorometholone (Flu), Dorzolamide (Dor), Timolol (Timol)) that are frequently marketed in Korea and evaluated their stability during storage according to the actual usage method after opening. The Olo had a decrease in assay and preservative content at 2 months after opening, while Flu showed a significant difference from day 28 after opening. For Dor, significant differences were observed from day 14 after opening in the assay and impurity test item and Timol showed a significant difference from day 28 after opening. Based on the results of the stability test Olo and Flu should only be used within 28 days of opening, while Dor and Timol should be used within 14 days of opening. Therefore, we suggest that regulations system related use periods of multi-use ophthalmic solutions designed as aseptic preparations should be improved based on the results of stability tests after opening.

키워드

Table 1. 2016, 3Q, IMS health data, Market share of ophthalmic solutions.

SHGSCZ_2019_v20n2_681_t0001.png 이미지

Table 2. Characteristic of ophthalmic solutions for in-use stability study after opening.

SHGSCZ_2019_v20n2_681_t0002.png 이미지

Table 3. In-use stability test design for determining beyond-use date of study ophthalmic solutions.

SHGSCZ_2019_v20n2_681_t0003.png 이미지

Table 4. HPLC conditions for in-use stability test of study products.

SHGSCZ_2019_v20n2_681_t0004.png 이미지

Table 5. In-use stability result of ophthalmic solutions at storage temperature 2~8℃.

SHGSCZ_2019_v20n2_681_t0005.png 이미지

Table 6. In-use stability result of ophthalmic solutions at storage temperature RT(room temperature).

SHGSCZ_2019_v20n2_681_t0006.png 이미지

참고문헌

  1. S. Bajaj, D. Signla, N. Sakhuja, "Stability Testing of Pharmaceutical Products", Journal of Applied Pharmaceutical Science, 02(03), 129-138, 2012.
  2. B. Kommanaboyina, C.T. Rhodes, "Trends in Stability Testing, with Emphasis on Stability During Distribution and Storage", Drug Dev. Ind. Pharm, 25, 857-867, 1999. DOI: https://doi.org/10.1081/DDC-100102246
  3. G.T. Kulkarni, G. Kuppusamy, B. Suresh, "Stability testing of pharmaceutical products: An overview", Indian J. Pharm. Educ, 38(4), 194-202, 2004.
  4. K.C. Waterman, L. Chen, P. Waterman, B.C. Macdonald, A.P. Monahan, G. Scrivens, "Modeling of in-use stability for tablets and powders in bottles", Drug Dev. Ind. Pharm, 42(10), 1571-1578, 2016. DOI: https://doi.org/10.3109/03639045.2016.1153648
  5. R.T. Magari, E. Afonina, "In-use stability modeling", J. Pharm. Biomed. Anal, 56, 799-803, 2011. DOI: https://doi.org/10.1016/j.jpba.2011.07.004
  6. N.R. Woo, N.J. Lee, S.J. Lee, M.Y. Kim, M.J. Park, J.P. Lee, W. Shin, "In-use Stability Study of Phloroglucinol and Nitroglycerin Sublingual Tablets Using Simulation Design after Opening of their Containers", Korean Journal of Pharm society, 61(6), pp. 281-285, 2017. DOI: https://doi.org/10.17480/psk.2017.61.6.281
  7. MFDS(Ministry of Food and Drug Safety), "The Korean Pharmacopoeia (KP11)" [Annex 2], 6.1 ophthalmic solutions, Korea, 2018.
  8. B.R. Matthews, G.M. Wall, "Stability Storage and Testing of Ophthalmic Products for Global Registration", Drug Dev. Ind. Pharm, 26(12), 1227-1237, 2000. DOI: https://doi.org/10.1081/DDC-100102304
  9. C. Rundfeldt, "Drug Development-A case study based insight into modern strategies (D. Mars, M. Birkhoff, "Multi-Dose Container for Nasal and Ophthalmic Drugs: A Preservative Free Future?)", Aptar Pharma, Consumer Healthcare Division, Germany, 509-524, 2011.
  10. EZ-DRUG (https://ezdrug.mfds.go.kr/)
  11. Korea consumer agency, "Analysis report of misuse eye-drop from misidentification of eye-drop", Korea, 2018 (http://www.kca.go.kr/brd/m_46/list.do)
  12. K.H. Kim, J.R. Oh, J.H. Kim, H.M. Kim, "Bacteria-Filtering Effect of a Filtering System Used in Eye Drops", J Korean Ophthalmol Soc, 48(10), 1329-1334, 2007. DOI: https://doi.org/10.3341/jkos.2007.48.10.1329
  13. B. Teuchner, J. Wagner, N.E. Bechrakis, D.O. Holler, M. Nagl, "Microbial Contamination of Glaucoma Eyedrops Used by Patients Compared With Ocular Medications Used in the Hospital", Journal Medicine, 94(8), 583-588, 2015 DOI: https://doi.org/10.1097/MD.0000000000000583
  14. D.P. Freeman, M.Y. Kahook, "Preservatives in topical ophthalmic medications: historical and clinical perspectives", Expert Rev Ophthalmol, 4(1), 59-64, 2009. DOI: https://doi.org/10.1586/17469899.4.1.59
  15. A. Tsegaw, T. Abula, Y. Assefa, "Bacterial Contamination of Multi-dose Eye Drops at Ophthalmology Department, University of Gondar, Northwest Ethiopia", Middle East Afr J Ophthalmol, 24(2), 81-86, 2017. DOI: https://doi.org/10.4103/meajo.MEAJO_308_16
  16. Note for guidance on in-use stability testing of human medicinal products, EMA, 2001.
  17. U.S. Pharmacopoeia National Formulary, USP General Chapters: <795> Pharmaceutical Compounding-Non sterile Preparations.
  18. U.S. Pharmacopoeia National Formulary, USP General Chapters: <797> Pharmaceutical Compounding-sterile Preparations.
  19. U.S. Pharmacopoeia National Formulary, USP General notice and requirements.
  20. Guideline on Stability Testing for Pharmaceuticals after Opening, MFDS, 2016.
  21. Shu Chiao Lin, Chin Fen Huang, Li Jiuan Shen, Hsueh Ju Wang, Chia Yu Lin, Fe Lin lin wu, "Formulation and stability of an extemporaneous 0.02% chlohexidine digluconate ophthalmic solution". Journal of the Formosan Medical Association, 2015; 114: 1162-1169, 2015. DOI: https://doi.org/10.1016/j.jfma.2014.08.003
  22. M.J. Park, N.H. Joeng, "Stability evaluation of cefaclor dry syrup after opening with simulation design", J Oil Chemists Soc. Korea, 2017(3): 151-152, 2017.
  23. S.D. Han, C.K. Kim, "Comparative Study on the Stability of Amoxicillin, Clavulanic Acid and its Commercial Combination Products", J. Pharm. Soc. Korea, 49(5), 392-398, 2005.
  24. Regulation on Pharmaceuticals Approval, Nortification and Review, MFDS, 2017.
  25. R.B. Matthews, "Regulatory Aspects of Stability Testing in Europe", Drug Dev. Ind. Pharm, 25, 831-856, 1999. DOI: https://doi.org/10.1081/DDC-100102245
  26. Danijela A. Kostic, Snezana S. Mitic, Danijela C. Naskovic, Aleksandra R. Zarubica, and Milan N. Mitic "Determination of Benzalkonium Chloride in Nasal Drops by High-Performance Liquid Chromatography", E-Journal of Chemistry, Volume 9, Issue 3, Pages 1599-1604, 2012. DOI: https://dx.doi.org/10.1155/2012/172070
  27. L.M Jurkic, M. Buratovic, I. Valentic, D. Stanfel, "UHPLC study on the degradation profiles of olopatadine hydrochloride in eye drops subjected to heat and filtration methods of sterilisation", Chromatographia, 77, pp. 1067-1080, 2014. DOI: https://doi.org/10.1007/s10337-014-2712-y
  28. Maha A. Hegazy, May H. Abdelwahab, Hassan A.M.Mendawy, Soheir A. Weshahy, Samah S. A bbas, "Validated HPTLC and HPLC methods for determination of fluorometholone and sodium crmoglycate in presence of their impurities and degradation products; application to kinetic study and on rabbit aqueous humor". J. Liquid chromatography & related technologies, 41(5), pp. 203-222, 2018. DOI: https://doi.org/10.1080/10826076.2018.1431926
  29. Harry Brittain, "Analytical profiles of drug substancs and excipients 26th", Academic press, 1999.
  30. N. Sharma, S.S. Rao, A.M. Reddy, "A novel and rapid validated stability-indicating UPLC method of related substances for dorzolamide hydrochloride and timolol maleate in ophthalmic dosage form", J. Chromatogr. Sci, 50(9), 745-755, 2012. DOI: https://doi.org/10.1093/chromsci/bms025
  31. S.P. Kulkarni, P.D. Amin, "Stability indicating HPTLC determination of timolol maleate as bulk drug and in pharmaceutical preparations", J. Pharm. Biomed. Anal, 23(6), 983-987, 2000. DOI: https://doi.org/10.1016/S0731-7085(00)00389-7
  32. E.Y. Tu, M.E. Shoff, W. Gao, C.E. Joslin, "Effect of low concentrations of benzalkonium chloride on acanthamoebal survival and its potential impact on empirical therapy of infectious keratitis", JAMA Ophthalmol, 131(5), 595-600, 2013. DOI: https://doi.org/10.1001/jamaophthalmol.2013.1644
  33. M.Q. Rahman, D. Tejwani, J.A. Wilson, I. Butcher, K. Ramaesh, "Microbial contamination of preservative free eye drops in multiple application containers", Br. J. Ophthalmol, 90(2), 139-141, 2006. DOI: https://doi.org/10.1136/bjo.2005.078386
  34. Y.H. Lee, "Microbial Contamination of Topical Eye Drugs", J Korean ophthalmol Soc. 37(5), 879-886, 1996.